Catalyst
Slingshot members are tracking this event:
Intra-Cellular Therapies (ITC) Announces U.S. FDA Approval of CAPLYTA (lumateperone) for the Treatment of Bipolar Depression in Adults
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ITCI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 20, 2021
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Lumateperone, Caplyta, Bipolar Depression
